Showing results (1-10 of 259) with videos related to

Sort By:
Pageof 26
Blood Research|April 28, 2022
<i>FLT3</i> mutations in acute myeloid leukemia: a review focusing on clinically applicable drugsJae-Sook Ahn, Hyeoung-Joon Kim
Clinical & Developmental Immunology|April 7, 2012
Immunotherapy using dendritic cells against multiple myeloma: how to improve?Thanh-Nhan Nguyen-Pham, Yoon-Kyung Lee, Hyeoung-Joon Kim, et al.
The Journal of Biological Chemistry|March 24, 2006
Chemical modification of santonin into a diacetoxy acetal form confers the ability to induce differentiation of human promyelocytic leukemia cells via the down-regulation of NF-kappaB DNA binding activitySeung Hyun Kim, Ju Han Song, Bo Gil Choi, et al.
International Journal of Oncology|March 25, 2008
Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacinJu Han Song, Seung Hyun Kim, Hyeoung-Joon Kim, et al.
Blood Research|July 5, 2013
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendationsYoo-Jin Kim, Jun Ho Jang, Jae-Yong Kwak, et al.
Critical Reviews in Oncology/Hematology|March 6, 2017
Immunotherapy for the treatment of multiple myelomaSung-Hoon Jung, Hyun-Ju Lee, Manh-Cuong Vo, et al.
Experimental & Molecular Medicine|August 19, 2010
Change in serum proteome during allogeneic hematopoietic stem cell transplantation and clinical significance of serum C-reactive protein and haptoglobinJoohyun Ryu, Se Ryeon Lee, Sung Goo Park, et al.
International Journal of Hematology|September 2, 2015
A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromesJun Ho Jang, Hironori Harada, Hirohiko Shibayama, et al.
Haematologica|May 12, 2004
Clinical efficacy and prediction of response to granulocyte transfusion therapy for patients with neutropenia-related infectionsJe-Jung Lee, Ho-Chun Song, Ik-Joo Chung, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 4, 2022
FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activationTaewoo Yang, Kyu-Young Sim, Gwang-Hoon Ko, et al.
Pageof 26